March 5, 2020 10:13 AM ESTUpdated 03:33 PM
People
Financing

Af­ter a trend­set­ting role in glob­al biotech ven­ture in­vest­ing, David Mott parts ways with NEA

John Carroll

Editor & Founder

About 12 years ago, David Mott jumped from the CEO suite at Med­Im­mune — af­ter As­traZeneca bought it for $15.6 bil­lion — in­to one of the busiest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times